Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary<i>N</i>-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash(Ionis Pharmaceuticals (United States)), Punit P. Seth(Ionis Pharmaceuticals (United States)), Shuling Guo(Ionis Pharmaceuticals (United States)), Sheri Booten(Ionis Pharmaceuticals (United States)), Heather F. Murray(Ionis Pharmaceuticals (United States)), Susan Murray(Ionis Pharmaceuticals (United States)), Brett P. Monia(Ionis Pharmaceuticals (United States)), Audrey Low(Ionis Pharmaceuticals (United States)), Mariam Aghajan(Ionis Pharmaceuticals (United States)), Alfred E. Chappell(Ionis Pharmaceuticals (United States)), Jinghua Yu(Tianjin University), Chenguang Zhao(Xijing Hospital), Rick Carty(Ionis Pharmaceuticals (United States)), Stan Riney(Ionis Pharmaceuticals (United States)), Karsten Schmidt(Ionis Pharmaceuticals (United States)), Mark J. Graham(Ionis Pharmaceuticals (United States)), Walt F. Lima(Ionis Pharmaceuticals (United States)), Eric E. Swayze(Ionis Pharmaceuticals (United States)), Jeff Crosby(Ionis Pharmaceuticals (United States)), Hans Gaus(Ionis Pharmaceuticals (United States))
Cited by 594
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
|Hepatology|2007|1k
Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression
|Journal of Biological Chemistry|1993|770